Press room

mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America.

The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019.

The laboratory mAbxience, which is part of Insud Pharma, has inaugurated a new biosimilar monoclonal antibody plant in Garín, Buenos Aires (Argentina).

Exeltis USA, Inc. a division of the global pharmaceutical group Insud Pharma, announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Slynd™ (pronounced "slind") containing drospirenone 4 mg, an oral contraceptive tablet for pregnancy prevention.

 

•This award is recognition of the hard work and dedication of Silvia Gold, President of the Mundo Sano Foundation, in changing the course of Chagas disease.

•Mundo Sano is currently running the campaign Not a Single Baby with Chagas, to ensure that all babies and women of reproductive age have access to diagnosis and treatment.

•Chagas disease affects 8 million people worldwide. In Spain, there are estimated to be between 50,000 and 100,000 Chagas sufferers. Globally, almost 9,000 babies are born with Chagas disease every year.

Insud Pharma group have once again been rated “very good” in the 2018 edition of the Spanish government’s Profarma Programme, thanks to its industrial activity and commitment to R&D.

• "Not a Single Baby with Chagas" is a reflection of the Foundation’s commitment to ensuring that by 2030 all babies born with Chagas disease can be treated and cured, and that all women of reproductive age have access to diagnosis and treatment.
• Every hour, a baby is born somewhere in the world with Chagas disease. It is estimated that 9,000 babies are born with the disease every year. 
• Chagas disease affects 8 million people worldwide; in Spain alone, at least 50,000 people are infected.

BioDan, a 3D dressing derived from human skin which can be bioprinted and frozen, Brainguard, a wearable system that predicts migraines, and Insulclock, a system which monitors and controls the treatment of diabetes patients are the three startups selected in the second round of the ChemoStart accelerator programme, which seeks to support innovative, disruptive solutions that improve people’s health and wellbeing. 

The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups

In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January